CureVac N.V. (CVAC) is looking forward to a strong quarter

CureVac N.V. (NASDAQ: CVAC) stock jumped 1.06% on Friday to $10.46 against a previous-day closing price of $10.35. With 1.64 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.85 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $10.74 whereas the lowest price it dropped to was $10.22. The 52-week range on CVAC shows that it touched its highest point at $23.32 and its lowest point at $5.63 during that stretch. It currently has a 1-year price target of $17.86.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CVAC was down-trending over the past week, with a drop of -2.24%, but this was up by 58.48% over a month. Three-month performance surged to 42.70% while six-month performance fell -24.96%. The stock lost -53.45% in the past year, while it has gained 73.47% so far this year. A look at the trailing 12-month EPS for CVAC yields -0.70 with Next year EPS estimates of -1.13. For the next quarter, that number is -0.31. This implies an EPS growth rate of -207.50% for this year and -10.90% for next year.

Float and Shares Shorts:

At present, 189.56 million CVAC shares are outstanding with a float of 88.88 million shares on hand for trading. On Oct 13, 2022, short shares totaled 2.69 million, which was 1.44% higher than short shares on Sep 14, 2022. In addition to Dr. Franz-Werner Haas L.L.M., LL.M., LLD, Ph.D. as the firm’s CEO, Member of Management Board & MD, Mr. Pierre Kemula B.Sc. serves as its MD, CFO & Member of Management Board.

Institutional Ownership:

Through their ownership of 20.84% of CVAC’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 2.08% of CVAC, in contrast to 1.91% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in CVAC with 0.91% of the stake, Bill & Melinda Gates Foundation T holds 1,709,781 shares worth 1,709,781. A second-largest stockholder of CVAC, BlackRock Fund Advisors, holds 582,066 shares, controlling over 0.31% of the firm’s shares. Millennium Management LLC is the third largest shareholder in CVAC, holding 536,032 shares or 0.29% stake. With a 0.32% stake in CVAC, the iShares Biotechnology ETF is the largest stakeholder. A total of 599,466 shares are owned by the mutual fund manager. The Government Pension Fund – Global, which owns about 0.25% of CVAC stock, is the second-largest Mutual Fund holder. It holds 472,962 shares valued at 2.85 million. iShares Tr. – Core MSCI EAFE ETF holds 0.16% of the stake in CVAC, owning 292,302 shares worth 1.76 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CVAC since 10 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 4 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 1 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CVAC analysts setting a high price target of $31.48 and a low target of $9.40, the average target price over the next 12 months is $16.73. Based on these targets, CVAC could surge 200.96% to reach the target high and fall by -10.13% to reach the target low. Reaching the average price target will result in a growth of 59.94% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. CVAC will report FY 2022 earnings on 02/28/2024. Analysts have provided yearly estimates in a range of -$0.80 being high and -$1.07 being low. For CVAC, this leads to a yearly average estimate of -$0.94. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. CureVac N.V. surprised analysts by $0.02 when it reported -$0.26 EPS against a consensus estimate of -$0.28. The surprise factor in the prior quarter was -$0.05. Based on analyst estimates, the high estimate for the next quarter is -$0.21 and the low estimate is -$0.43. The average estimate for the next quarter is thus -$0.31.

Leave a Comment

Your email address will not be published. Required fields are marked *